argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
On July 22, 2021, argenx (Euronext & Nasdaq: ARGX) announced a conference call scheduled for July 29, 2021, at 2:30 p.m. CET to discuss its half-year 2021 financial results and provide a business update for the second quarter.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
On July 22, 2021, argenx (Euronext & Nasdaq: ARGX) announced a conference call scheduled for July 29, 2021, at 2:30 p.m. CET to discuss its half-year 2021 financial results and provide a business update for the second quarter. The live call will be accessible via the Investors section on the argenx website, with a replay available for a year. argenx focuses on innovative antibody-based therapies for severe autoimmune diseases and cancer, and is actively evaluating multiple candidates in serious indications.
Positive
- The upcoming conference call will provide insights into half-year financial performance.
- Discussions will cover updates on the company’s pipeline, including efgartigimod.
Negative
- None.
Details
News Market Reaction – ARGX
The recorded move for ARGX in the trading session of this news was -0.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
July 22, 2021
Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.
A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.
Dial-in numbers:
Please dial in 15 minutes prior to the live call.
Belgium 0800 389 13
France 0805 102 319
Netherlands 0800 949 4506
United Kingdom 0800 279 9489
United States 1 844 808 7140
International 1 412 902 0128
About argenx
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit www.argenx.com and follow us on LinkedIn at https://www.linkedin.com/company/argenx/ and Twitter at https://twitter.com/argenxglobal.
For further information, please contact:
Media:
Kelsey Kirk
kkirk@argenx.com
Joke Comijn
jcomijn@argenx.com
Investors:
Beth DelGiacco
bdelgiacco@argenx.com
Michelle Greenblatt
mgreenblatt@argenx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.